SRC and Familial prostate cancer: Supporting the role of Src in the progression of prostate cancer, immunohistochemistry of prostate tissue from the transgenic adenocarcinoma mouse prostate model shows a progressive increase (up to threefold) in positive staining of activated Src, as a function of age and cancer progression from 8 to 24 weeks (36).